<ul>
<li>Myriad Genetics 股票因遺傳性癌症檢測而大幅上漲</li>
</ul>
<p>Quest Diagnostics Incorporated (NYSE:DGX - 免費報告) - Leerink Partnrs 在 10 月 21 日星期二向投資者發佈的報告中下調了對 Quest Diagnostics 2025 財年第四季度每股收益的預期。Leerink Partnrs 分析師 M. Cherny 現在預計該醫療研究公司本季度每股收益為 2.39 美元，低於之前的 2.45 美元預期。Quest Diagnostics 當前全年的共識每股收益預期為 9.70 美元。</p>
<p>獲取 <strong>Quest Diagnostics</strong> 警報：</p>
<p>其他一些券商也對 DGX 發表了評論。摩根士丹利在週三的研究報告中將 Quest Diagnostics 的目標股價設定為 207.00 美元，並給予該公司 “增持” 評級。瑞穗證券在 10 月 17 日星期五將 Quest Diagnostics 的目標股價從 190.00 美元上調至 210.00 美元，並給予該公司 “跑贏大盤” 評級。威廉·布萊爾在 7 月 23 日星期三的研究報告中重申了對 Quest Diagnostics 的 “跑贏大盤” 評級。瑞銀集團在 10 月 17 日星期五的研究報告中將 Quest Diagnostics 的目標股價從 180.00 美元上調至 190.00 美元，並給予該公司 “中性” 評級。最後，德意志銀行在 7 月 23 日星期三的研究報告中將 Quest Diagnostics 的目標股價從 160.00 美元上調至 178.00 美元，並給予該公司 “持有” 評級。一位分析師給予該股票 “強烈買入” 評級，八位分析師給予 “買入” 評級，十位分析師給予 “持有” 評級。根據 MarketBeat.com 的數據，該公司目前的共識評級為 “適度買入”，共識目標價為 196.31 美元。</p>
<ul>
<li>LifeMD 股票因 GLP-1 業務增長而復甦</li>
</ul>
<p><strong>獲取我們關於 DGX 的最新報告</strong></p>
<h2>Quest Diagnostics 股票上漲 1.2%</h2>
<p>DGX 股票在週五以 183.29 美元開盤。Quest Diagnostics 的 52 周低點為 148.70 美元，52 周高點為 197.55 美元。該公司的市值為 203.9 億美元，市盈率為 21.51，市盈率增長比率為 2.39，貝塔值為 0.56。該公司的 50 日簡單移動平均線為 182.94 美元，200 日簡單移動平均線為 176.62 美元。該公司的債務與股本比率為 0.71，速動比率為 0.99，流動比率為 1.13。</p>
<ul>
<li>Exact Sciences 準確滿足投資者的期望</li>
</ul>
<p>Quest Diagnostics (NYSE:DGX - 獲取免費報告) 最近在 10 月 21 日星期二公佈了季度財報。該醫療研究公司報告本季度每股收益為 2.60 美元，超出分析師共識預期的 2.51 美元，超出幅度為 0.09 美元。Quest Diagnostics 的淨利潤率為 8.91%，股本回報率為 15.47%。該公司本季度的收入為 28.2 億美元，而分析師預期為 27.3 億美元。在去年同期，該公司每股收益為 2.30 美元。Quest Diagnostics 的季度收入同比增長 13.2%。Quest Diagnostics 已將其 2025 財年的指導目標設定為 9.760-9.840 每股收益。</p>
<h2>Quest Diagnostics 宣佈分紅</h2>
<p>該公司最近還宣佈了一項季度分紅，該分紅於 10 月 20 日星期一支付。10 月 3 日星期五的股東獲得每股 0.80 美元的分紅。這相當於每年 3.20 美元的分紅，分紅收益率為 1.7%。除息日期為 10 月 3 日星期五。Quest Diagnostics 的分紅支付比率目前為 38.32%。</p>
<h2>內部人士下注</h2>
<p>在其他消息中，高級副總裁 Michael E. Prevoznik 於 9 月 23 日星期二出售了 28,288 股公司的股票。股票以平均價格 187.12 美元出售，總交易額為 5,293,250.56 美元。出售完成後，該高級副總裁持有 38,117 股公司的股票，價值約為 7,132,453.04 美元。這代表其持股比例減少了 42.60%。該交易在向 SEC 提交的法律文件中披露，文件可通過此鏈接訪問。此外，高級副總裁 Patrick Plewman 於 8 月 6 日星期三出售了 5,535 股公司的股票。該股票以平均價格 175.00 美元出售，總交易額為 968,625.00 美元。出售後，該高級副總裁直接持有 19,219 股公司的股票，價值約為 3,363,325 美元。該交易代表其持股比例減少了 22.36%。該交易的披露信息可以在此找到。內部人士在上個季度共出售了價值 9,647,471 美元的 53,186 股公司股票。公司內部人士持有公司股票的 8.16%。</p>
<h2>Quest Diagnostics 的機構交易</h2>
<p>一些機構投資者和對沖基金最近對該公司的持倉進行了調整。俄勒岡州公共僱員退休基金在第三季度將其在 Quest Diagnostics 的持股增加了 32.1%。俄勒岡州公共僱員退休基金目前擁有 12,763 股該醫療研究公司的股票，價值 2,432,000 美元，在此期間又增持了 3,100 股。Nisa Investment Advisors LLC 在第三季度將其在 Quest Diagnostics 的持股增加了 61.8%。Nisa Investment Advisors LLC 目前擁有 18,050 股該醫療研究公司的股票，價值 3,440,000 美元，在此期間又增持了 6,892 股。G&amp;S Capital LLC 在第三季度將其在 Quest Diagnostics 的持股增加了 117.1%。G&amp;S Capital LLC 目前擁有 15,249 股該醫療研究公司的股票，價值 2,906,000 美元，在此期間又增持了 8,225 股。Steigerwald Gordon &amp; Koch Inc.在第三季度購買了 Quest Diagnostics 的新股份，價值約 47,000 美元。最後，Benjamin Edwards Inc.在第三季度將其在 Quest Diagnostics 的持股增加了 2.1%。Benjamin Edwards Inc.目前擁有 6,891 股該醫療研究公司的股票，價值 1,313,000 美元，在此期間又增持了 140 股。機構投資者持有該公司 88.06% 的股票。</p>
<h2>Quest Diagnostics 公司簡介</h2>
<p>(獲取免費報告)</p>
<p>Quest Diagnostics Incorporated 在美國和國際上提供診斷測試和服務。該公司開發並提供診斷信息服務，包括常規、非常規和高級臨牀測試、解剖病理測試及其他診斷信息服務。</p>
<h2>精選故事</h2>
<ul>
<li>五隻我們更看好的股票，而不是 Quest Diagnostics</li>
<li>股票評級和推薦：理解分析師評級</li>
<li>華納兄弟競標戰潛力：WBD 股票能漲多高？</li>
<li>上升趨勢股票解析：學習如何利用上升趨勢進行交易</li>
<li>分析師預計 Netflix 在第三季度財報崩潰後有 30% 的上漲空間</li>
<li>風險承受能力因人而異</li>
<li>O’Reilly Automotive 的股票價格上升趨勢將在 2026 年繼續</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPURHWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPURHWA"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Quest Diagnostics 嗎？</h2>
<p>在考慮 Quest Diagnostics 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Quest Diagnostics 並不在名單上。</p>
<p>雖然 Quest Diagnostics 目前在分析師中有中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

奎斯特診療

<p>Leerink Partners 將 Quest Diagnostics (NYSE:DGX) 2025 年第四季度每股收益（EPS）預估從 $2.45 下調至 $2.39。市場對該公司全年收益的共識預估為每股 $9.70。多家券商對 DGX 設置了目標價，其中摩根士丹利為 $207.00，瑞穗為 $210.00。Quest Diagnostics 最近報告的季度每股收益為 $2.60，超出預期，並宣佈季度股息為每股 $0.80。該股開盤價為 $183.29，市值為 $203.9 億，市盈率為 21.51</p>

<ul>
<li>Myriad Genetics Sees Stock Surge with Hereditary Cancer Tests</li>
</ul>
<div class="lb-trans"><ul>
<li>Myriad Genetics 股票因遺傳性癌症檢測而大幅上漲</li>
</ul>
</div><p>Quest Diagnostics Incorporated (NYSE:DGX - Free Report) - Leerink Partnrs reduced their Q4 2025 EPS estimates for shares of Quest Diagnostics in a note issued to investors on Tuesday, October 21st. Leerink Partnrs analyst M. Cherny now expects that the medical research company will earn $2.39 per share for the quarter, down from their prior estimate of $2.45. The consensus estimate for Quest Diagnostics' current full-year earnings is $9.70 per share.</p>
<div class="lb-trans"><p>Quest Diagnostics Incorporated (NYSE:DGX - 免費報告) - Leerink Partnrs 在 10 月 21 日星期二向投資者發佈的報告中下調了對 Quest Diagnostics 2025 財年第四季度每股收益的預期。Leerink Partnrs 分析師 M. Cherny 現在預計該醫療研究公司本季度每股收益為 2.39 美元，低於之前的 2.45 美元預期。Quest Diagnostics 當前全年的共識每股收益預期為 9.70 美元。</p>
</div><p>Get <strong>Quest Diagnostics</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Quest Diagnostics</strong> 警報：</p>
</div><p>A number of other brokerages have also commented on DGX. Morgan Stanley set a $207.00 price target on shares of Quest Diagnostics and gave the company an &#34;overweight&#34; rating in a research note on Wednesday. Mizuho upped their price target on shares of Quest Diagnostics from $190.00 to $210.00 and gave the company an &#34;outperform&#34; rating in a research note on Friday, October 17th. William Blair reiterated an &#34;outperform&#34; rating on shares of Quest Diagnostics in a research note on Wednesday, July 23rd. UBS Group upped their price target on shares of Quest Diagnostics from $180.00 to $190.00 and gave the company a &#34;neutral&#34; rating in a research note on Friday, October 17th. Finally, Deutsche Bank Aktiengesellschaft upped their price target on shares of Quest Diagnostics from $160.00 to $178.00 and gave the company a &#34;hold&#34; rating in a research note on Wednesday, July 23rd. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and ten have issued a Hold rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $196.31.</p>
<div class="lb-trans"><p>其他一些券商也對 DGX 發表了評論。摩根士丹利在週三的研究報告中將 Quest Diagnostics 的目標股價設定為 207.00 美元，並給予該公司 “增持” 評級。瑞穗證券在 10 月 17 日星期五將 Quest Diagnostics 的目標股價從 190.00 美元上調至 210.00 美元，並給予該公司 “跑贏大盤” 評級。威廉·布萊爾在 7 月 23 日星期三的研究報告中重申了對 Quest Diagnostics 的 “跑贏大盤” 評級。瑞銀集團在 10 月 17 日星期五的研究報告中將 Quest Diagnostics 的目標股價從 180.00 美元上調至 190.00 美元，並給予該公司 “中性” 評級。最後，德意志銀行在 7 月 23 日星期三的研究報告中將 Quest Diagnostics 的目標股價從 160.00 美元上調至 178.00 美元，並給予該公司 “持有” 評級。一位分析師給予該股票 “強烈買入” 評級，八位分析師給予 “買入” 評級，十位分析師給予 “持有” 評級。根據 MarketBeat.com 的數據，該公司目前的共識評級為 “適度買入”，共識目標價為 196.31 美元。</p>
</div><ul>
<li>LifeMD Shares Come Back to Life on GLP-1 Business Growth</li>
</ul>
<div class="lb-trans"><ul>
<li>LifeMD 股票因 GLP-1 業務增長而復甦</li>
</ul>
</div><p><strong>Get Our Latest Report on DGX</strong></p>
<div class="lb-trans"><p><strong>獲取我們關於 DGX 的最新報告</strong></p>
</div><h2>Quest Diagnostics Stock Up 1.2%</h2>
<div class="lb-trans"><h2>Quest Diagnostics 股票上漲 1.2%</h2>
</div><p>Shares of DGX opened at $183.29 on Friday. Quest Diagnostics has a 52 week low of $148.70 and a 52 week high of $197.55. The firm has a market cap of $20.39 billion, a P/E ratio of 21.51, a price-to-earnings-growth ratio of 2.39 and a beta of 0.56. The firm's 50-day simple moving average is $182.94 and its 200 day simple moving average is $176.62. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.99 and a current ratio of 1.13.</p>
<div class="lb-trans"><p>DGX 股票在週五以 183.29 美元開盤。Quest Diagnostics 的 52 周低點為 148.70 美元，52 周高點為 197.55 美元。該公司的市值為 203.9 億美元，市盈率為 21.51，市盈率增長比率為 2.39，貝塔值為 0.56。該公司的 50 日簡單移動平均線為 182.94 美元，200 日簡單移動平均線為 176.62 美元。該公司的債務與股本比率為 0.71，速動比率為 0.99，流動比率為 1.13。</p>
</div><ul>
<li>Exact Sciences Serves Investors Exactly What They Wished For</li>
</ul>
<div class="lb-trans"><ul>
<li>Exact Sciences 準確滿足投資者的期望</li>
</ul>
</div><p>Quest Diagnostics (NYSE:DGX - Get Free Report) last announced its quarterly earnings results on Tuesday, October 21st. The medical research company reported $2.60 EPS for the quarter, beating analysts' consensus estimates of $2.51 by $0.09. Quest Diagnostics had a net margin of 8.91% and a return on equity of 15.47%. The business had revenue of $2.82 billion for the quarter, compared to analyst estimates of $2.73 billion. During the same quarter in the prior year, the business earned $2.30 EPS. Quest Diagnostics's quarterly revenue was up 13.2% on a year-over-year basis. Quest Diagnostics has set its FY 2025 guidance at 9.760-9.840 EPS.</p>
<div class="lb-trans"><p>Quest Diagnostics (NYSE:DGX - 獲取免費報告) 最近在 10 月 21 日星期二公佈了季度財報。該醫療研究公司報告本季度每股收益為 2.60 美元，超出分析師共識預期的 2.51 美元，超出幅度為 0.09 美元。Quest Diagnostics 的淨利潤率為 8.91%，股本回報率為 15.47%。該公司本季度的收入為 28.2 億美元，而分析師預期為 27.3 億美元。在去年同期，該公司每股收益為 2.30 美元。Quest Diagnostics 的季度收入同比增長 13.2%。Quest Diagnostics 已將其 2025 財年的指導目標設定為 9.760-9.840 每股收益。</p>
</div><h2>Quest Diagnostics Announces Dividend</h2>
<div class="lb-trans"><h2>Quest Diagnostics 宣佈分紅</h2>
</div><p>The firm also recently announced a quarterly dividend, which was paid on Monday, October 20th. Shareholders of record on Friday, October 3rd were given a dividend of $0.80 per share. This represents a $3.20 dividend on an annualized basis and a dividend yield of 1.7%. The ex-dividend date was Friday, October 3rd. Quest Diagnostics's dividend payout ratio is presently 38.32%.</p>
<div class="lb-trans"><p>該公司最近還宣佈了一項季度分紅，該分紅於 10 月 20 日星期一支付。10 月 3 日星期五的股東獲得每股 0.80 美元的分紅。這相當於每年 3.20 美元的分紅，分紅收益率為 1.7%。除息日期為 10 月 3 日星期五。Quest Diagnostics 的分紅支付比率目前為 38.32%。</p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>內部人士下注</h2>
</div><p>In other news, SVP Michael E. Prevoznik sold 28,288 shares of the company's stock in a transaction that occurred on Tuesday, September 23rd. The shares were sold at an average price of $187.12, for a total transaction of $5,293,250.56. Following the completion of the sale, the senior vice president owned 38,117 shares of the company's stock, valued at approximately $7,132,453.04. This represents a 42.60% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, SVP Patrick Plewman sold 5,535 shares of the company's stock in a transaction that occurred on Wednesday, August 6th. The stock was sold at an average price of $175.00, for a total transaction of $968,625.00. Following the sale, the senior vice president directly owned 19,219 shares of the company's stock, valued at approximately $3,363,325. This trade represents a 22.36% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 53,186 shares of company stock worth $9,647,471 in the last quarter. Corporate insiders own 8.16% of the company's stock.</p>
<div class="lb-trans"><p>在其他消息中，高級副總裁 Michael E. Prevoznik 於 9 月 23 日星期二出售了 28,288 股公司的股票。股票以平均價格 187.12 美元出售，總交易額為 5,293,250.56 美元。出售完成後，該高級副總裁持有 38,117 股公司的股票，價值約為 7,132,453.04 美元。這代表其持股比例減少了 42.60%。該交易在向 SEC 提交的法律文件中披露，文件可通過此鏈接訪問。此外，高級副總裁 Patrick Plewman 於 8 月 6 日星期三出售了 5,535 股公司的股票。該股票以平均價格 175.00 美元出售，總交易額為 968,625.00 美元。出售後，該高級副總裁直接持有 19,219 股公司的股票，價值約為 3,363,325 美元。該交易代表其持股比例減少了 22.36%。該交易的披露信息可以在此找到。內部人士在上個季度共出售了價值 9,647,471 美元的 53,186 股公司股票。公司內部人士持有公司股票的 8.16%。</p>
</div><h2>Institutional Trading of Quest Diagnostics</h2>
<div class="lb-trans"><h2>Quest Diagnostics 的機構交易</h2>
</div><p>A number of institutional investors and hedge funds have recently made changes to their positions in the company. Oregon Public Employees Retirement Fund lifted its holdings in shares of Quest Diagnostics by 32.1% during the 3rd quarter. Oregon Public Employees Retirement Fund now owns 12,763 shares of the medical research company's stock worth $2,432,000 after acquiring an additional 3,100 shares during the period. Nisa Investment Advisors LLC lifted its holdings in shares of Quest Diagnostics by 61.8% during the 3rd quarter. Nisa Investment Advisors LLC now owns 18,050 shares of the medical research company's stock worth $3,440,000 after acquiring an additional 6,892 shares during the period. G&amp;S Capital LLC lifted its holdings in shares of Quest Diagnostics by 117.1% during the 3rd quarter. G&amp;S Capital LLC now owns 15,249 shares of the medical research company's stock worth $2,906,000 after acquiring an additional 8,225 shares during the period. Steigerwald Gordon &amp; Koch Inc. bought a new stake in shares of Quest Diagnostics during the 3rd quarter worth approximately $47,000. Finally, Benjamin Edwards Inc. lifted its holdings in shares of Quest Diagnostics by 2.1% during the 3rd quarter. Benjamin Edwards Inc. now owns 6,891 shares of the medical research company's stock worth $1,313,000 after acquiring an additional 140 shares during the period. Institutional investors own 88.06% of the company's stock.</p>
<div class="lb-trans"><p>一些機構投資者和對沖基金最近對該公司的持倉進行了調整。俄勒岡州公共僱員退休基金在第三季度將其在 Quest Diagnostics 的持股增加了 32.1%。俄勒岡州公共僱員退休基金目前擁有 12,763 股該醫療研究公司的股票，價值 2,432,000 美元，在此期間又增持了 3,100 股。Nisa Investment Advisors LLC 在第三季度將其在 Quest Diagnostics 的持股增加了 61.8%。Nisa Investment Advisors LLC 目前擁有 18,050 股該醫療研究公司的股票，價值 3,440,000 美元，在此期間又增持了 6,892 股。G&amp;S Capital LLC 在第三季度將其在 Quest Diagnostics 的持股增加了 117.1%。G&amp;S Capital LLC 目前擁有 15,249 股該醫療研究公司的股票，價值 2,906,000 美元，在此期間又增持了 8,225 股。Steigerwald Gordon &amp; Koch Inc.在第三季度購買了 Quest Diagnostics 的新股份，價值約 47,000 美元。最後，Benjamin Edwards Inc.在第三季度將其在 Quest Diagnostics 的持股增加了 2.1%。Benjamin Edwards Inc.目前擁有 6,891 股該醫療研究公司的股票，價值 1,313,000 美元，在此期間又增持了 140 股。機構投資者持有該公司 88.06% 的股票。</p>
</div><h2>Quest Diagnostics Company Profile</h2>
<div class="lb-trans"><h2>Quest Diagnostics 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(獲取免費報告)</p>
</div><p>Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.</p>
<div class="lb-trans"><p>Quest Diagnostics Incorporated 在美國和國際上提供診斷測試和服務。該公司開發並提供診斷信息服務，包括常規、非常規和高級臨牀測試、解剖病理測試及其他診斷信息服務。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精選故事</h2>
</div><ul>
<li>Five stocks we like better than Quest Diagnostics</li>
<li>Stock Ratings and Recommendations: Understanding Analyst Ratings</li>
<li>Warner Bros. Bidding War Potential: How High Could WBD Shares Go?</li>
<li>Uptrend Stocks Explained: Learn How to Trade Using Uptrends</li>
<li>Analysts Eye 30% Upside in Netflix After Q3 Earnings Crash</li>
<li>With Risk Tolerance, One Size Does Not Fit All</li>
<li>O’Reilly Automotive’s Stock Price Uptrend Will Continue in 2026</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，而不是 Quest Diagnostics</li>
<li>股票評級和推薦：理解分析師評級</li>
<li>華納兄弟競標戰潛力：WBD 股票能漲多高？</li>
<li>上升趨勢股票解析：學習如何利用上升趨勢進行交易</li>
<li>分析師預計 Netflix 在第三季度財報崩潰後有 30% 的上漲空間</li>
<li>風險承受能力因人而異</li>
<li>O’Reilly Automotive 的股票價格上升趨勢將在 2026 年繼續</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPURHWA" alt="" original-src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NYSE&amp;Symbol=DGX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Quest Diagnostics Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Quest Diagnostics 嗎？</h2>
</div><p>Before you consider Quest Diagnostics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Quest Diagnostics 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Quest Diagnostics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Quest Diagnostics 並不在名單上。</p>
</div><p>While Quest Diagnostics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Quest Diagnostics 目前在分析師中有中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

Leerink Partners 對奎斯特診療的收益發布了悲觀的估計